Trials / Conditions / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma

Stage I Cutaneous T-cell Non-Hodgkin Lymphoma

19 registered clinical trials studyying Stage I Cutaneous T-cell Non-Hodgkin Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymp NCT03409432	John Reneau	Phase 2
Unknown	Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT02232516	Northwestern University	Phase 2
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma NCT01800838	Kevin Cooper MD	Phase 1
Terminated	Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma NCT01738594	Northwestern University	Phase 1
Terminated	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037	Northwestern University	Phase 1 / Phase 2
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Completed	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494	Wake Forest University Health Sciences	N/A
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718	University of Washington	Phase 1 / Phase 2
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Terminated	Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides NCT00052377	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846	Fred Hutchinson Cancer Center	Phase 2
Completed	506U78 in Treating Patients With Lymphoma NCT00005080	National Cancer Institute (NCI)	Phase 2
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A
Terminated	O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma NCT00003613	National Cancer Institute (NCI)	Phase 1